Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

<p>Background: There is often a finite progression-free interval of time between one systemic therapy and the next when treating patients with advanced cancer. While it appears that progression-free survival (PFS) between systemic therapies tends to get shorter for a number of factors, there h...

Full description

Bibliographic Details
Main Author: Christopher H. Bailey, Gayle Jameson, Chao Sima, Sharon Fleck, Erica White, Daniel D. Von Hoff, Glen J. Weiss
Format: Article
Language:English
Published: Ivyspring International Publisher 2012-01-01
Series:Journal of Cancer
Online Access:http://www.jcancer.org/v03p0007.htm